Medexus Pharmaceuticals Inc is seeing a notable rise in its stock price, reflecting investor optimism around its recent performance and strategic initiatives.
On the TSX, Medexus Pharmaceuticals Inc (MDP.TO) saw its stock price increase by 2.96% in the last trading session, closing at CA$4.17. This uptick comes amid positive developments for the company, especially regarding its flagship product, GRAFAPEX.
Investor takeaway: Investors may find Medexus an attractive opportunity as the company demonstrates strong product performance and strategic initiatives aimed at enhancing shareholder value.
Advertisement
Medexus Pharmaceuticals Inc
MDP.TO
MDP.TO
Medexus Pharmaceuticals Inc
WealthAwesomeAdvertisement
Market cap
$160.20M
52W high
$5.25
52W low
$2.47
1W change
+2.05%
Beta
1.84
Analyst Price Targets
Based on analyst covering MDP
Wall Street analysts forecast MDP stock price to rise 36.7% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$6.81
+36.7% Upside
Current Price
C$4.98
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDP's historical volatility
30-Day Vol
49.8%
Annualized
90-Day Vol
42.4%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$5.95
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$5.29 | C$4.45 – C$6.28 |
| 60 trading days | C$5.61 | C$4.40 – C$7.15 |
| 90 trading days | C$5.95 | C$4.42 – C$8.02 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Medexus Pharmaceuticals Inc stock rises 2.96% today
Advertisement
The stock's increase reflects a market capitalization of approximately CA$131.8 million, indicating investor confidence in the company's growth potential.
Bull case
Medexus recently reported a significant increase in demand for GRAFAPEX, with net revenues reaching CA$3.1 million in the recent fiscal Q3 2026 results. This strong performance suggests that the company is growing its market presence and has potential for future revenue growth.
Bear case
Despite the positive movement, Medexus's profit margin remains negative at -0.0027, which indicates ongoing challenges in achieving profitability. Investors should remain cautious about the company's financial health and market volatility.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
